OmniAb, Inc.
OmniAb, Inc. (trading on The Capital Market) operates as a leading provider of cutting-edge antibody discovery technology platforms licensed to pharmaceutical, biotechnology, and academic institutions worldwide. The company's core business centers on its proprietary OmniAb technology platform, which enables partners… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What OmniAb, Inc. does
In the company’s own words
OmniAb, Inc. (trading on The Capital Market) operates as a leading provider of cutting-edge antibody discovery technology platforms licensed to pharmaceutical, biotechnology, and academic institutions worldwide. The company's core business centers on its proprietary OmniAb technology platform, which enables partners to discover next-generation therapeutic antibodies through advanced screening and identification methodologies. At the heart of the platform lies Biological Intelligence, powered by genetically engineered transgenic animals that produce optimized antibody candidates for human therapeutics.
The company's technology suite includes multiple proprietary transgenic animal platforms: OmniRat, OmniMouse, OmniChicken, OmniFlic, OmniClic, OmnidAb, OmniTaur, and the newly launched OmniUltra. These platforms are complemented by screening technologies including the AI-powered xPloration platform and GEM technology, alongside computational tools collectively known as OmniDeep. The company also possesses specialized capabilities in ion channel and transporter discovery, representing a significant competitive differentiator.
As of December 31, 2025, OmniAb maintained 107 active partners utilizing 407 active programs across its technology platform. The company's portfolio includes 27 OmniAb-derived antibodies in clinical development by partners, two products under regulatory review, and three approved products already commercialized. The business model aligns OmniAb's interests with partners through structured licensing agreements typically incorporating upfront or annual access fees, service revenue, milestone payments, and royalties on commercial sales.
OmniAb's competitive advantages stem from its multi-species transgenic platform, which the company believes comprises the most diverse host systems available in the industry. The company has built its technology portfolio through strategic acquisitions including Open Monoclonal Technology, Crystal Bioscience, Ab Initio Biotherapeutics, Icagen's ion channel assets, xCella Biosciences, and Taurus Biosciences, combined with continuous internal innovation. The company's website is located at www.omniab.com. OmniAb is classified as a smaller reporting company and emerging growth company for regulatory purposes.
Company details
- Sector
- Industrials
- Industry
- Professional Services
- Headquarters
- EMERYVILLE, CA
- Fiscal year end
- December
- CIK
- 1846253
- SIC
- 8731
Financial performance, year by year
Fiscal 2022–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns OmniAb, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · OmniAb, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do OmniAb, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of OmniAb, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in OmniAb, Inc.'s last four quarterly filings that the numbers alone won't show?”